Northwire Canada EditionSaturday, July 18, 2026
Sign inSubscribe
Northwire
⌕
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%
Earnings

Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025

By The Northwire Desk — AI Analysis Oct 31, 2025 · 02:34 4565 · None None
4565 · Price

Executive Summary

  • Nxera Pharma reported Q3 2025 financial results, showing a net loss of ¥4.81 bn and an operating loss of ¥5.91 bn, widening versus the prior period.
  • The company launched its proprietary obesity pipeline (oral GLP‑1 agonist plus six GPCR programs) and dosed the first patient in a Phase 2a cancer immunotherapy trial (HTL0039732).
  • Milestone payments of US$10 m were received from AbbVie under the multi‑target discovery collaboration, and additional manufacturing capacity was approved in Japan for QUVIVIQ®.

Key Details

  • Financial Highlights (9‑month period ended 30 Sep 2025)
  • Revenue: ¥21.848 bn (US$147.4 m), down ¥135 m YoY.
  • R&D expense: ¥11.200 bn (US$75.6 m), up ¥2.683 bn YoY.
  • SG&A expense: ¥11.410 bn (US$77.0 m), down ¥307 m YoY.
  • Operating loss: ¥5.907 bn (US$39.9 m) vs. ¥2.846 bn loss prior period.
  • Loss before tax: ¥6.838 bn (US$46.1 m).
  • Net loss: ¥4.809 bn (US$32.5 m).
  • Core operating loss: ¥986 m (US$6.6 m) vs. core profit of ¥4.425 bn prior period.

  • Cash & cash equivalents: ¥28.461 bn (US$191.5 m), down ¥3.807 bn YoY.

  • Operational Highlights – Q3 2025

  • Launched proprietary obesity pipeline: oral small‑molecule GLP‑1 agonist + six GPCR‑targeted programs using NxWave™ platform.
  • First patient dosed in Phase 2a trial of HTL0039732 (oral EP4 antagonist) for solid cancers, sponsored by Cancer Research UK.

  • Received US$10 m R&D milestone from AbbVie under multi‑target discovery collaboration focused on neurological GPCR targets.

  • Post‑Period Events

  • Cancer Research UK presented Phase 1 data for HTL’732 at ESMO 2025; trial met objectives, identified dose for ongoing Phase 2 expansion.

  • Japan’s Ministry of Health approved a partial amendment to add an additional manufacturing site in Asia for QUVIVIQ® (25 mg & 50 mg), expected to lower costs and support the 2030 profitability vision.

  • Milestone Payments

  • AbbVie collaboration milestone: US$10 m received during the quarter.

Notable Quotes

“During the third quarter of 2025, we made strong progress in advancing our plans for obesity and metabolic diseases… Our newly launched proprietary pipeline… positions Nxera to play a leading role in shaping the next generation of metabolic therapies.” – Chris Cargill, President & CEO

All figures are as presented by Nxera Pharma and converted at the rates disclosed in the release.

Read the original news release →

More from None

Jun 30, 2026 · 04:27

AI-driven GPCR drug discovery platform monetizing partnerships while transitioning to a profitable specialty pharma model in APAC.

Other Jun 10, 2026 · 02:35

AI-driven GPCR drug discovery platform accelerates pipeline through strategic consortium membership and milestone-driven revenue turnaround.

M&A / Property Jun 01, 2026 · 19:30

Nxera Accelerates Vamorolone Rollout in South Korea as APAC Specialty Pharma Strategy Gains Traction

Regulatory May 11, 2026 · 02:34

GPCR spin-out reels in $275M in biobucks and equity, keeping Asia rights and cash burn in check

M&A / Property May 08, 2026 · 06:26

Nxera Pharma Defends Core IP Amidst Profitability Turnaround

Regulatory May 01, 2026 · 02:36

Nxera Pharma Turns Profitable on Milestone Surge, But Cash Burn Raises Liquidity Questions

Earnings